Roivant Sciences Files 8-K: Financial Statements & Exhibits
Ticker: ROIV · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1635088
Sentiment: neutral
Topics: disclosure, financial-statements, exhibits
TL;DR
Roivant Sciences filed an 8-K, mostly standard financial docs. Nothing major to see here.
AI Summary
On December 3, 2024, Roivant Sciences Ltd. filed an 8-K report. The filing primarily serves as a notification of financial statements and exhibits, as well as a Regulation FD disclosure. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Roivant Sciences is providing necessary financial documentation and adhering to disclosure regulations, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any new material risks or events.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- December 3, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Roivant Sciences Ltd.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, and to serve as a Regulation FD disclosure.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is December 3, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 7th Floor 50 Broadway London SW1H 0DB United Kingdom.
What is Roivant Sciences Ltd.'s telephone number?
Roivant Sciences Ltd.'s telephone number is +44 207 400-3347.
Is Roivant Sciences Ltd. incorporated in the United States?
No, Roivant Sciences Ltd. is incorporated in Bermuda.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-12-03 07:20:26
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
Filing Documents
- ef20039426_8k.htm (8-K) — 29KB
- ef20039426_ex99-1.htm (EX-99.1) — 18KB
- 0001140361-24-048238.txt ( ) — 187KB
- roiv-20241203.xsd (EX-101.SCH) — 4KB
- roiv-20241203_lab.xml (EX-101.LAB) — 21KB
- roiv-20241203_pre.xml (EX-101.PRE) — 16KB
- ef20039426_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclo sure. On December 3, 2024, Roivant Sciences Ltd. (the "Company") issued a press release announcing topline results from Kinevant's Phase 2 RESOLVE-Lung study of namilumab in chronic active pulmonary sarcoidosis. As noted in the press release, namilumab failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROIVANT SCIENCES LTD. Date: December 3, 2024 By: /s/ Keyur Parekh Name: Keyur Parekh Title: Authorized Signatory